Keywords
Pirarubicin
Electroresection
Bladder cancer
Submitted : 2023-09-25
Accepted : 2023-10-10
Published : 2023-10-25
Abstract
Objective: This paper aims to compare the effects of gemcitabine and pirarubicin in treating bladder cancer after electroresection. Methods: Bladder cancer patients who underwent bladder cancer resection in our hospital from January 2018 to January 2022 were selected as research subjects. According to the computer grouping method, 60 patients were divided into Group A (pirarubicin) and Group B (gemcitabine), and the therapeutic effects of the two groups of patients were compared. Results: The statistical significance of the tumor markers and related factor levels of patients in Group A and Group B before treatment was not established (P > 0.05). The levels of tumor markers and related factors of patients in Group B after treatment were lower than those of Group A (P < 0.05). There was no difference in the quality of life scores of patients in Group A and Group B before treatment (P > 0.05). After treatment, the quality of life scores of patients in Group B was higher than those in Group A (P < 0.05). The incidence rates of dysuria, hematuria, cystitis, and rash in Group B patients were less than those in group A (P < 0.05). The recurrence rate of patients in Group B was higher than in group A (P < 0.05). Conclusion: Both gemcitabine and pirarubicin are commonly used chemotherapy drugs after electroresection for bladder cancer. Compared with pirarubicin, gemcitabine is more effective and can improve the quality of life of bladder cancer patients.
References
Wang S, Li J, Li B, et al., 2022, Effects of Gemcitabine and Pirarubicin Alone or in Combination after PKRBT for Non-Muscle Invasive Bladder Cancer. Chinese Journal of Gerontology, 42(15): 3653–3656.
Cheng Q, Wang K, Zhu X, 2021, Effect of Intravesical Gemcitabine Chemotherapy on Recurrence after Transurethral Resection of Bladder Tumors in Patients with Non-Muscle Invasive Bladder Cancer. Cancer Progress, 19(3): 268–271.
Liu L, Ma P, Lu C, et al., 2022, Clinical Efficacy of Sequential Intravesical Instillation of Gemcitabine and Pirarubicin in Patients with Non-Muscle Invasive Bladder Cancer who Underwent Urethral Bladder Tumor Resection. Drugs Evaluation Research, 45(11): 2311–2317.
Wu D, Li Q, Peng N, et al., 2021, Analysis of Pirarubicin and Gemcitabine Hyperthermic Intravesical Chemotherapy Application in Elderly Patients with Superficial Bladder Cancer after TURBT. Huaihai Medicine, 39(5): 514–516.
Landong, Huang G, Lan J, et al., 2021, Study on the Differences in Adverse Reactions and Recurrence of Intravesical Infusion between Gemcitabine and Pirarubicin after Resection of Non-Muscle Invasive Bladder Cancer. Chinese Medical Frontiers Journal (Electronic Edition), 13(10): 67–70.
Suo D, Zhao B, Wang W, et al., 2022, Effects of Modified Zhibai Dihuang Decoction Combined with Pirarubicin on Tumor Markers, Immune Function and Quality of Life in Patients with Non-Muscle Invasive Bladder Cancer after Surgery. Journal of Modern Integrated Traditional Chinese and Western Medicine, 31(11): 1542–1545, 1586.
Shen J, Ma X, Ma D, et al., 2022, The Effect of Laparoscopic Radical Cystectomy Combined with Pirarubicin in Treating Bladder Tumors and its Impact on Serum CA125 and ?-FR Levels. International Journal of Urology, 42(2): 207–210.
Li X, Li H, Fan Z, et al., 2022, Meta-Analysis of the Effectiveness and Safety of Gemcitabine in Bladder Cancer. Journal of Pharmaceutical Sciences of the People’s Liberation Army, 35(6): 541–547.
Duan W, Guan Z, Zhao H, et al., 2021, Effect of Oral Silibinin Capsules Combined with Intravesical Pirarubicin on Postoperative Recurrence in Patients with Non-Muscle Invasive Bladder Cancer. Modern Oncology Medicine, 29(10): 1728–1732.
Tang P, Huang Z, Yan Y, et al., 2021, Randomized Controlled Study on the Efficacy of Oral Administration of Houpu Tongguan Decoction Combined with Pirarubicin Intravesical Chemotherapy in Patients with Postoperative Non-Muscle Invasive Bladder Cancer. Second Military Medical University Journal of Chinese Journal of Science and Technology, 42(10): 1107–1114.
Yi H, Du Y, Zhu H, 2021, Comparative Analysis of the Efficacy of Pirarubicin and BCG Instillation in Preventing the Recurrence of High-Risk Non-Muscle Invasive Bladder Cancer. International Journal of Urology, 41(3): 408–411.
Chen S, Wei Y, Ahemati S, et al., 2022, Analysis of the Efficacy of Gemcitabine Combined with Cisplatin Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. Journal of Practical Oncology, 237(5): 457–464.
Yan Q, Pan Y, Xi X, et al., 2022, Analysis of the Impact of Alternating Intravesical Instillation of Gemcitabine and BCG on the Prognosis of Elderly Patients with High-Risk Non-Muscle Invasive Bladder Cancer after Transurethral Resection of Bladder Tumors. Practical Hospital Clinic Magazine, 19(5): 89–91.
Zhang X, 2022, Study on the Effect of Neoadjuvant Chemotherapy Regimen of Gemcitabine Combined with Cisplatin in the Treatment of Advanced Localized Bladder Cancer. Journal of Practical Cancer, 37(4): 656–658, 663.
Gui Q, Huang X, Zhang K, et al., 2022, Application Effect of Gemcitabine and Epirubicin in Thermal Perfusion Therapy after Transurethral Resection of Superficial Bladder Cancer. Cancer Progress, 20(19): 2007–2010, 2014.